MEASLES-VIRUS AND C3 BINDING-SITES ARE DISTINCT ON MEMBRANE COFACTOR PROTEIN (CD46)

被引:119
作者
MANCHESTER, M
VALSAMAKIS, A
KAUFMAN, R
LISZEWSKI, MK
ALVAREZ, J
ATKINSON, JP
LUBLIN, DM
OLDSTONE, MBA
机构
[1] UNIV CALIF SAN DIEGO, MED CTR, DEPT PATHOL, SAN DIEGO, CA 92103 USA
[2] WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV LAB MED, ST LOUIS, MO 63110 USA
[3] WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL, ST LOUIS, MO 63110 USA
关键词
D O I
10.1073/pnas.92.6.2303
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The human complement regulatory protein membrane cofactor protein (CD46) is the cellular receptor for measles virus (MV), whereas decay accelerating factor (DAF; CD55), a structurally similar complement regulatory protein, does not bind MV. To characterize the interaction between MV and CD46, mutants of the CD46 protein and hybrid molecules between CD46 and DAF were tested for their ability to act as MV receptors. The transmembrane domain and cytoplasmic tail of CD46 were not required for receptor function as cells expressing the CD46 extracellular domain linked to the glycosyl-phosphatidylinositol tail of DAF were rendered susceptible to MV infection. Chimeric proteins exchanging the four extracellular short consensus repeat (SCR) domains between CD46 and DAF indicated that only molecules with both SCR1 and SCR2 from CD46 allowed a productive MV infection. Further, monoclonal antibodies (mAbs) against SCR1 or SCR2 of CD46 blocked MV infection, whereas a mAb against SCR3 and SCR4 did not. The latter mAb blocks C3b/C4b binding (which maps to SCR3 and SCR4) whereas the former mAbs do not. Thus, our data indicate that both SCR1 and SCR2 make up the MV receptor determinant in CD46. These results also suggest avenues for development of therapeutic agents to inhibit MV binding and thus infection and disease.
引用
收藏
页码:2303 / 2307
页数:5
相关论文
共 26 条
  • [11] EXPRESSION OF MEMBRANE INTERLEUKIN-1 BY FIBROBLASTS TRANSFECTED WITH MURINE PRO-INTERLEUKIN-1-ALPHA CDNA
    FUHLBRIGGE, RC
    FINE, SM
    UNANUE, ER
    CHAPLIN, DD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) : 5649 - 5653
  • [12] CHILD-MORTALITY AFTER HIGH-TITER MEASLES-VACCINES - PROSPECTIVE-STUDY IN SENEGAL
    GARENNE, M
    LEROY, O
    BEAU, JP
    SENE, I
    [J]. LANCET, 1991, 338 (8772) : 903 - 907
  • [13] THE REGULATORS OF COMPLEMENT ACTIVATION (RCA) GENE-CLUSTER
    HOURCADE, D
    HOLERS, VM
    ATKINSON, JP
    [J]. ADVANCES IN IMMUNOLOGY, 1989, 45 : 381 - 416
  • [14] HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21
  • [15] DISULFIDE BONDS ARE LOCALIZED WITHIN THE SHORT CONSENSUS REPEAT UNITS OF COMPLEMENT REGULATORY PROTEINS - C4B-BINDING PROTEIN
    JANATOVA, J
    REID, KBM
    WILLIS, AC
    [J]. BIOCHEMISTRY, 1989, 28 (11) : 4754 - 4761
  • [16] MAPPING OF THE C3B-BINDING SITE OF CR-1 AND CONSTRUCTION OF A (CR1)2-F(AB')2 CHIMERIC COMPLEMENT INHIBITOR
    KALLI, KR
    HSU, PH
    BARTOW, TJ
    AHEARN, JM
    MATSUMOTO, AK
    KLICKSTEIN, LB
    FEARON, DT
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) : 1451 - 1460
  • [17] KRYCH M, 1994, J BIOL CHEM, V269, P13273
  • [18] MEMBRANE COFACTOR PROTEIN (MCP OR CD46) - NEWEST MEMBER OF THE REGULATORS OF COMPLEMENT ACTIVATION GENE-CLUSTER
    LISZEWSKI, MK
    POST, TW
    ATKINSON, JP
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 : 431 - 455
  • [19] PHOSPHOLIPID-ANCHORED AND TRANSMEMBRANE VERSIONS OF EITHER DECAY-ACCELERATING FACTOR OR MEMBRANE COFACTOR PROTEIN SHOW EQUAL EFFICIENCY IN PROTECTION FROM COMPLEMENT-MEDIATED CELL-DAMAGE
    LUBLIN, DM
    COYNE, KE
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) : 35 - 44
  • [20] BINDING OF MEASLES-VIRUS TO MEMBRANE COFACTOR PROTEIN (CD46) - IMPORTANCE OF DISULFIDE BONDS AND N-GLYCANS FOR THE RECEPTOR FUNCTION
    MAISNER, A
    SCHNEIDERSCHAULIES, J
    LISZEWSKI, MK
    ATKINSON, JP
    HERRLER, G
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (10) : 6299 - 6304